| UniProt ID | CO4A3_HUMAN | |
|---|---|---|
| UniProt AC | Q01955 | |
| Protein Name | Collagen alpha-3(IV) chain | |
| Gene Name | COL4A3 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 1670 | |
| Subcellular Localization | Secreted, extracellular space, extracellular matrix, basement membrane. Colocalizes with COL4A4 and COL4A5 in GBM, tubular basement membrane (TBM) and synaptic basal lamina (BL).. | |
| Protein Description | Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen.; Tumstatin, a cleavage fragment corresponding to the collagen alpha 3(IV) NC1 domain, possesses both anti-angiogenic and anti-tumor cell activity; these two anti-tumor properties may be regulated via RGD-independent ITGB3-mediated mechanisms.. | |
| Protein Sequence | MSARTAPRPQVLLLPLLLVLLAAAPAASKGCVCKDKGQCFCDGAKGEKGEKGFPGPPGSPGQKGFTGPEGLPGPQGPKGFPGLPGLTGSKGVRGISGLPGFSGSPGLPGTPGNTGPYGLVGVPGCSGSKGEQGFPGLPGTLGYPGIPGAAGLKGQKGAPAKEEDIELDAKGDPGLPGAPGPQGLPGPPGFPGPVGPPGPPGFFGFPGAMGPRGPKGHMGERVIGHKGERGVKGLTGPPGPPGTVIVTLTGPDNRTDLKGEKGDKGAMGEPGPPGPSGLPGESYGSEKGAPGDPGLQGKPGKDGVPGFPGSEGVKGNRGFPGLMGEDGIKGQKGDIGPPGFRGPTEYYDTYQEKGDEGTPGPPGPRGARGPQGPSGPPGVPGSPGSSRPGLRGAPGWPGLKGSKGERGRPGKDAMGTPGSPGCAGSPGLPGSPGPPGPPGDIVFRKGPPGDHGLPGYLGSPGIPGVDGPKGEPGLLCTQCPYIPGPPGLPGLPGLHGVKGIPGRQGAAGLKGSPGSPGNTGLPGFPGFPGAQGDPGLKGEKGETLQPEGQVGVPGDPGLRGQPGRKGLDGIPGTPGVKGLPGPKGELALSGEKGDQGPPGDPGSPGSPGPAGPAGPPGYGPQGEPGLQGTQGVPGAPGPPGEAGPRGELSVSTPVPGPPGPPGPPGHPGPQGPPGIPGSLGKCGDPGLPGPDGEPGIPGIGFPGPPGPKGDQGFPGTKGSLGCPGKMGEPGLPGKPGLPGAKGEPAVAMPGGPGTPGFPGERGNSGEHGEIGLPGLPGLPGTPGNEGLDGPRGDPGQPGPPGEQGPPGRCIEGPRGAQGLPGLNGLKGQQGRRGKTGPKGDPGIPGLDRSGFPGETGSPGIPGHQGEMGPLGQRGYPGNPGILGPPGEDGVIGMMGFPGAIGPPGPPGNPGTPGQRGSPGIPGVKGQRGTPGAKGEQGDKGNPGPSEISHVIGDKGEPGLKGFAGNPGEKGNRGVPGMPGLKGLKGLPGPAGPPGPRGDLGSTGNPGEPGLRGIPGSMGNMGMPGSKGKRGTLGFPGRAGRPGLPGIHGLQGDKGEPGYSEGTRPGPPGPTGDPGLPGDMGKKGEMGQPGPPGHLGPAGPEGAPGSPGSPGLPGKPGPHGDLGFKGIKGLLGPPGIRGPPGLPGFPGSPGPMGIRGDQGRDGIPGPAGEKGETGLLRAPPGPRGNPGAQGAKGDRGAPGFPGLPGRKGAMGDAGPRGPTGIEGFPGPPGLPGAIIPGQTGNRGPPGSRGSPGAPGPPGPPGSHVIGIKGDKGSMGHPGPKGPPGTAGDMGPPGRLGAPGTPGLPGPRGDPGFQGFPGVKGEKGNPGFLGSIGPPGPIGPKGPPGVRGDPGTLKIISLPGSPGPPGTPGEPGMQGEPGPPGPPGNLGPCGPRGKPGKDGKPGTPGPAGEKGNKGSKGEPGPAGSDGLPGLKGKRGDSGSPATWTTRGFVFTRHSQTTAIPSCPEGTVPLYSGFSFLFVQGNQRAHGQDLGTLGSCLQRFTTMPFLFCNVNDVCNFASRNDYSYWLSTPALMPMNMAPITGRALEPYISRCTVCEGPAIAIAVHSQTTDIPPCPHGWISLWKGFSFIMFTSAGSEGTGQALASPGSCLEEFRASPFLECHGRGTCNYYSNSYSFWLASLNPERMFRKPIPSTVKAGELEKIISRCQVCMKKRH | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 2 | Phosphorylation | ------MSARTAPRP ------CCCCCCCCH | 37.45 | 22210691 | |
| 5 | Phosphorylation | ---MSARTAPRPQVL ---CCCCCCCCHHHH | 40.50 | 22210691 | |
| 28 | Phosphorylation | LAAAPAASKGCVCKD HHHCHHHHCCCEECC | 31.52 | 22210691 | |
| 235 | Phosphorylation | ERGVKGLTGPPGPPG CCCCCCCCCCCCCCC | 57.20 | - | |
| 243 | Phosphorylation | GPPGPPGTVIVTLTG CCCCCCCEEEEEEEC | 16.91 | - | |
| 249 | Phosphorylation | GTVIVTLTGPDNRTD CEEEEEEECCCCCCC | 36.98 | - | |
| 253 | N-linked_Glycosylation | VTLTGPDNRTDLKGE EEEECCCCCCCCCCC | 52.46 | UniProtKB CARBOHYD | |
| 382 | Phosphorylation | GPPGVPGSPGSSRPG CCCCCCCCCCCCCCC | 21.73 | - | |
| 386 | Phosphorylation | VPGSPGSSRPGLRGA CCCCCCCCCCCCCCC | 48.70 | 24719451 | |
| 835 | Phosphorylation | QQGRRGKTGPKGDPG CCCCCCCCCCCCCCC | 62.63 | - | |
| 1001 | Ubiquitination | GPRGDLGSTGNPGEP CCCCCCCCCCCCCCC | 40.20 | 17370265 | |
| 1059 | Phosphorylation | DKGEPGYSEGTRPGP CCCCCCCCCCCCCCC | 35.15 | 24719451 | |
| 1206 | Methylation | FPGLPGRKGAMGDAG CCCCCCCCCCCCCCC | 57.86 | - | |
| 1206 | "N6,N6-dimethyllysine" | FPGLPGRKGAMGDAG CCCCCCCCCCCCCCC | 57.86 | - | |
| 1246 | Phosphorylation | GNRGPPGSRGSPGAP CCCCCCCCCCCCCCC | 38.96 | - | |
| 1249 | Phosphorylation | GPPGSRGSPGAPGPP CCCCCCCCCCCCCCC | 21.03 | - | |
| 1379 | Ubiquitination | QGEPGPPGPPGNLGP CCCCCCCCCCCCCCC | 44.14 | 17370265 | |
| 1401 | Phosphorylation | GKDGKPGTPGPAGEK CCCCCCCCCCCCCCC | 33.33 | 22210691 | |
| 1414 | Ubiquitination | EKGNKGSKGEPGPAG CCCCCCCCCCCCCCC | 75.79 | 17370265 | |
| 1422 | Phosphorylation | GEPGPAGSDGLPGLK CCCCCCCCCCCCCCC | 30.52 | 28111955 | |
| 1429 | Acetylation | SDGLPGLKGKRGDSG CCCCCCCCCCCCCCC | 69.19 | 23236377 | |
| 1435 | Phosphorylation | LKGKRGDSGSPATWT CCCCCCCCCCCCCEE | 43.95 | 7768924 | |
| 1443 | Phosphorylation | GSPATWTTRGFVFTR CCCCCEEECEEEEEE | 21.98 | - | |
| 1452 | Phosphorylation | GFVFTRHSQTTAIPS EEEEEECCCCCCCCC | 26.40 | 7768924 | |
| 1519 | Phosphorylation | NFASRNDYSYWLSTP CCCCCCCCCEEECCC | 13.75 | 24275569 | |
| 1525 | Phosphorylation | DYSYWLSTPALMPMN CCCEEECCCCCCCCC | 15.48 | 24275569 | |
| 1537 | Phosphorylation | PMNMAPITGRALEPY CCCCCCCCCCCCCCC | 21.40 | 24275569 | |
| 1544 | Phosphorylation | TGRALEPYISRCTVC CCCCCCCCHHHCEEE | 11.36 | 24275569 | |
| 1546 | Phosphorylation | RALEPYISRCTVCEG CCCCCCHHHCEEECC | 18.56 | 24275569 | |
| 1612 (in isoform 2) | Phosphorylation | - | 36.54 | 7758473 | |
| 1648 | Phosphorylation | MFRKPIPSTVKAGEL HHCCCCCCCCHHHHH | 46.69 | 22199227 | |
| 1649 | Phosphorylation | FRKPIPSTVKAGELE HCCCCCCCCHHHHHH | 22.22 | 22199227 |
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of CO4A3_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of CO4A3_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
Oops, there are no PPI records of CO4A3_HUMAN !! | ||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| Note=Autoantibodies against the NC1 domain of alpha 3(IV) are found in Goodpasture syndrome, an autoimmune disease of lung and kidney. | ||||||
| 203780 | ||||||
| 141200 | Hematuria, benign familial (BFH) | |||||
| 104200 | Alport syndrome, autosomal dominant (APSAD) | |||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Ubiquitylation | |
| Reference | PubMed |
| "Tryptic digestion of ubiquitin standards reveals an improved strategyfor identifying ubiquitinated proteins by mass spectrometry."; Denis N.J., Vasilescu J., Lambert J.-P., Smith J.C., Figeys D.; Proteomics 7:868-874(2007). Cited for: UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-1414, AND MASSSPECTROMETRY. | |